Cardiovascular disease is the leading cause of death worldwide. Cardiomyocytes have limited regenerative capacity; consequently, regenerative therapies are in high demand. There are currently several potential strategies for heart regeneration, with one approach involving in situ generation of new cardiomyocytes from endogenous cell sources. Direct cardiac reprogramming has emerged as a novel therapeutic approach to regenerating the damaged heart by directly converting endogenous cardiac fibroblasts into cardiomyocyte-like cells. Following our first report of direct cardiac reprogramming, significant advances have elucidated the molecular mechanisms associated with cardiac reprogramming. These advances have also improved cardiac-reprogramming efficiency by enabling direct in vivo cardiac reprogramming. Moreover, progress has been made in cardiac reprogramming of human fibroblasts. Although basic research has supported substantial progress in this field, numerous challenges remain in terms of clinical application. Here, we review the current state of cardiac reprogramming as a new technology for understanding and treating cardiovascular diseases.

The class 2 CRISPR-Cas endonuclease Cas12a (previously known as Cpf1) offers several advantages over Cas9, including the ability to process its own array and the requirement for just a single RNA guide. These attributes make Cas12a promising for many genome engineering applications. To further expand the suite of Cas12a tools available, we tested 16 Cas12a orthologs for activity in eukaryotic cells. Four of these new enzymes demonstrated targeted activity, one of which, from Moraxella bovoculi AAX11_00205 (Mb3Cas12a), exhibited robust indel formation. We also showed that Mb3Cas12a displays some tolerance for a shortened PAM (TTN versus the canonical Cas12a PAM TTTV). The addition of these enzymes to the genome editing toolbox will further expand the utility of this powerful technology.

The importance of aerobic fitness in rowing has been widely studied, and it is accepted that aerobic fitness is a key factor in rowing performance. In contrast, the impact of rowing efficacy, especially rowing form, on rowing performance has not yet been fully elucidated. The present study aimed to investigate this subject via the analysis of hip kinematics and the association of this variable with 2000 m ergometer rowing test performance. Eleven adult male rowers underwent a 2000 m rowing test on an ergometer and the exhaled gas was analyzed. The hip joint angle, the pelvic rotation, and the knee joint angle were measured at the catch position throughout the test. Peak VO₂ was strongly associated with the time taken to complete the test (ρ=–0.96, P<0.01), thereby confirming the importance of aerobic capacity in rowing performance. The variance of the hip joint angle of each rower was associated with peak VO₂, lean mass, and test time (ρ=–0.72, –0.84, and 0.66, respectively, all P<0.05). Greater knee flexion was accompanied by larger posterior rotation of the pelvis (ρ=0.74, P<0.05), and was negatively associated with hip flexion (ρ=–0.76, P<0.05). Although we cannot confirm whether the consistency of the hip joint angle actually leads to better rowing performance, our results suggest that there are associations between the consistency of the hip joint angle, aerobic capacity, lean mass, and the time taken to complete the 2000 m ergometer rowing test.